Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs TDOC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TDOC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 3–7 Matrix Metrics)

TDOC Overall Winner 6-Pillar Tally: CRSP 2 – 4 TDOC Matrix Metrics: CRSP 7 – 3 TDOC

As of Nov 16, 2026, Teladoc Health, Inc. (TDOC) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas TDOC carries 42.1/100 (HOLD) at $8.59 (N/M Forward P/E, -5.4% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. TDOC 42.1/100 HOLD), TDOC captures the overall institutional head-to-head verdict (3–7 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.4% vs. -2058.6% operating margin) and revenue trajectory (-3.4% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile TDOC trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs TDOC
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80
TDOC NYSE Head-to-Head Winner
Teladoc Health, Inc.
Services-Offices & Clinics Of Doctors Of Medicine
$8.59
-2.44% 1D
Market Cap $1.6B
TTM Revenue $2.47B
Forward P/E N/M
Beta / 30D Vol 0.83β · 108% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 24.0 Fund 36.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $8.02 · SMA50: $6.80

6-Pillar Scorecard Institutional Category Breakdown (CRSP 2 – 4 TDOC)

Columns: Metric · CRSP · TDOC
1. Valuation Multiples CRSP
Forward P/E 23.4x N/M
Trailing P/E 23.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.7x
2. Growth & Scale CRSP
Revenue Growth (YoY) +1325.1% -3.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $2.47B
Market Cap $4.1B $1.6B
3. Profitability & Quality TDOC
Gross Margin N/A 68.6%
Operating Margin -2058.6% -5.4%
Net Profit Margin 0.0% -6.3%
Return on Equity (ROE) -25.6% -11.5%
4. Balance Sheet & Cash Flow TDOC
Cash Generation (TTM) -$378M $126M
Cash Flow Margin N/A 5.1%
Net Cash / Leverage $588M Net Debt (0.47x D/E) $185M Net Debt (0.80x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TDOC
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 97.8% (52nd %ile) 59.2% (40th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.34x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat TDOC
OpEx & R&D Intensity N/A 74.0% of Rev ($1.83B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (7) vs TDOC (3)
Institutional Metric CRSP TDOC Criterion Row Edge
Market Capitalization
Scale
$4.1B $1.6B Larger Scale CRSP
Trailing P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% -3.4% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% -5.4% Higher Margin TDOC
Net Profit Margin
Profitability
0.0% -6.3% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-25.6% -11.5% Higher ROE TDOC
52-Week Range Position
Momentum
1% ($40–$63) 76% ($4–$10) Stronger Trend TDOC
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 0.83β · 108% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $2.47B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 68.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) $126M ($185M Net Debt (0.80x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TDOC +68.95 pp
CRSP: -17.54% · TDOC: +51.41%
3M Horizon TDOC +56.02 pp
CRSP: -23.33% · TDOC: +32.69%
6M Horizon TDOC +51.57 pp
CRSP: -16.37% · TDOC: +35.2%
1Y Horizon TDOC +41.97 pp
CRSP: -20.54% · TDOC: +21.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue TDOC Revenue CRSP Op. Margin TDOC Op. Margin Margin Leader
FY2018 $0M $420M -5087.8% -17.0% TDOC
FY2019 $290M $550M 16.1% -14.5% CRSP
FY2020 $0M $1.09B -49295.5% -46.3% TDOC
FY2021 $910M $2.03B 40.8% -13.1% CRSP
FY2022 $0M $2.41B -56190.4% -567.3% TDOC
FY2023 $370M $2.60B -60.0% -9.6% TDOC
FY2024 $40M $2.57B -1250.4% -39.7% TDOC
FY2025 $0M $2.53B -18933.6% -10.4% TDOC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TDOC CONSOLIDATION
93d in phase · OBV DISTRIBUTION
Current IV 59.2%
IV Percentile 40th %ile
Put/Call OI Skew 0.34x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TDOC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TDOC Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.6B market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment 74.0% of Rev ($1.83B)
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs TDOC Key Questions & Quantitative Answers

As of Nov 16, 2026, Teladoc Health, Inc. (TDOC) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas TDOC carries 42.1/100 (HOLD) at $8.59 (N/M Forward P/E, -5.4% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. TDOC 42.1/100 HOLD), TDOC captures the overall institutional head-to-head verdict (3–7 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.4% vs. -2058.6% operating margin) and revenue trajectory (-3.4% vs. +1325.1% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile TDOC trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with TDOC at -3.4% YoY revenue growth and +0.0% YoY earnings growth on $2.47B TTM revenue (68.6% gross margin, -5.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while TDOC shifted +502.4%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus 74.0% of Rev ($1.83B) (0 disclosures) for TDOC.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TDOC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (5.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus TDOC (-11.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, TDOC carries 59.2% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.83β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.